|
Market Cap (25-Jun) $19,510,578 (1,113th) |
Close (30-Jun) $0.049 |
Volume (30-Jun) 1,094,468 |
Shortsold (12-Jul) 1 (0.00%) (672nd) |
|
52w High $0.000 |
52w Low $0.000 |
P/E 20.45 |
EPS -0.02 |
PXS released this announcement to the ASX on 2 November 2020, 8:31. The announcement is marked as price sensitive, and is 3 page(s) in length and 136.14kb in size.
You can view all announcements from PXS and see how they appear on a price chart on the announcements page.
At the date of this announcement, PXS was 0.000% short sold according to ASIC data. It was ranked the 591st most shorted stock on the ASX. It remains ranked 672nd as of the latest reported data (12 July 2023).
| Other Recent Announcements from PXS | |
|---|---|
| Investor presentation | 24 May 2023, 8:21 |
| PXS Announces Encouraging Results from Phase 1c Scar Study | 23 May 2023, 16:32 |
| Trading Halt | 22 May 2023, 8:56 |
| Pharmaxis Prioritises Clinical Program on Myelofibrosis | 2 November 2020, 8:31 |
| FDA Approves Bronchitol for US Market | 2 November 2020, 8:29 |
| Appendix 4C - quarterly | 30 October 2020, 9:00 |
| September Quarter 2020 Activity Report | 30 October 2020, 8:59 |
You must be logged in to post a reply.
Pharmaxis Ltd 